Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID
The present invention is directed to compositions containing an anti-inflammatory compound that acts by blocking protein extravasation together with an NSAID. These compositions may be used to treat inflammation and pain, especially headache pain. The invention also includes methods in which these drugs are separately administered to a patient.
1 . A pharmaceutical composition in unit dose form, comprising:
a) an anti-inflammatory compound that acts by blocking protein extravasation; and
b) an NSAID;
wherein said anti-inflammatory compound and said NSAID are present in an amount effective to relieve pain upon the administration of one or more unit doses to a patient.
2 . The pharmaceutical composition of claim 1 , wherein said anti-inflammatory compound of paragraph a) is a NK-1 receptor antagonist.
3 . The pharmaceutical composition of claim 2 , wherein said NSAID has an onset of action of two hours or less.
4 . The pharmaceutical composition of claim 2 , wherein said anti-inflammatory compound and said NSAID are present in an amount sufficient to provide therapeutic synergy or migraine-related therapeutic synergy and wherein no more than one drug is present in an amount sufficient to provide a therapeutic effect in the absence of the other.
5 . The pharmaceutical composition of claim 2 , wherein said anti-inflammatory compound of paragraph a) is present in said unit dosage form at between 0.5 and 600 mg.
6 . The pharmaceutical composition of claim 5 , wherein said NSAID is present in said unit dosage form at 1-600 mg.
7 . The pharmaceutical composition of claim 6 , wherein said NSAID is selected from the group consisting of: aspirin; ibuprofen; acetaminophen; naproxen; diclofenac; ketorolac; etodolac; flurbiprofen; oxaprozin; indomethacin; mefenamic acid; nabumetone; piroxicam; celecoxib; rofecoxib; valdecoxib; and lornoxicam.
8 . The pharmaceutical composition of claim 1 , wherein:
a) said anti-inflammatory compound is an NK-1 antagonist at 1-600 mg; and
b) said NSAID is present at 1-600 mg, and is selected from the group consisting of: aspirin; ibuprofen; acetaminophen; naproxen; diclofenac; ketorolac; lomoxicam; and etodolac.
9 . A method of treating a patient for pain, inflammation or migraine, comprising: administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 1 .
10 . The method of claim 9 , wherein said anti-inflammatory compound in said pharmaceutical composition is an NK-1 receptor antagonist.
11 . The method of claim 10 , wherein said NSAID in said pharmaceutical composition is selected from the group consisting of: aspirin; ibuprofen; acetaminophen; naproxen; diclofenac; ketorolac; etodolac; flurbiprofen; oxaprozin; indomethacin; mefenamic acid; nabumetone; piroxicam; celecoxib; rofecoxib; valdecoxib; and lomoxicam.
12 . A method of treating a patient for pain, inflammation or migraine, comprising:
a) administering to said patient an NSAID; and
b) administering to said patient an anti-inflammatory compound that acts by blocking protein extravasation,
wherein said NSAID of step a) and said anti-inflammatory compound of step b) are administered in a co-timely manner and are administered in a therapeutically effective amount.
13 . The method of claim 12 , wherein said anti-inflammatory compound of step b) is administered within two hours of the NSAID of step a).
14 . The method of claim 13 , wherein said anti-inflammatory compound of step b) is an NK-1 antagonist.
15 . The method of claim 14 , wherein said NK-1 antagonist is administered within two hours of said NSAID.
16 . The method of claim 15 , wherein said NK-1 antagonist is administered within one hour of said NSAID.
17 . The method of claim 15 , wherein said NSAID and said anti-inflammatory compound of are administered in an amount sufficient to provide for therapeutic synergy or migraine-related therapeutic synergy and wherein no more than one drug is administered in an amount sufficient to provide a therapeutic effect in the absence of the other.
18 . The method of claim 17 , wherein said NSAID and said anti-inflammatory compound are each administered at a dose of 1-600 mg.
19 . The method of claim 18 , wherein said NSAID is selected from the group consisting of: aspirin; ibuprofen; acetaminophen; naproxen; diclofenac; ketorolac; etodolac; flurbiprofen; oxaprozin; indomethacin; mefenamic acid; nabumetone; piroxicam; celecoxib; rofecoxib; valdecoxib; and lomoxicam.
20 . The method of claim 19 , wherein said patient is treated for migraine.